HOME >> BIOLOGY >> NEWS
High Density Lipoproteins And Coronary Heart Disease

Renowned scientists in the field of lipid research will lead a symposium entitled High Density Lipoproteins and Coronary Heart Disease on Saturday, November 7, 1998 in Dallas, TX. Scientists will review the hypothesis that low levels of high-density lipoprotein (HDL) cholesterol are a risk for coronary heart disease; discuss metabolic disorders that result in this condition; and evaluate treatment options.

The symposium, accredited by Continuing Medical Education at The Johns Hopkins University School of Medicine, will include presentations by:

  • Ernst Schaefer, MD, chief, Lipid Metabolism Laboratory, USDA Human Nutrition Research Center at Tufts University
  • H. Bryan Brewer, MD, chief, Molecular Diseases Branch, National Heart, Lung, and Blood Institute, National Institutes of Health
  • Moti Kashyup, MD, director, Cholesterol Center, Veterans Affairs Medical Center
  • John Guyton, MD, director, Duke Lipid Clinic, Duke University Medical Center
  • Hanna Rubins, MD, associate professor of medicine, University of Minnesota School of Medicine. Dr. Rubins, the Lead Investigator for the High-Density Lipoprotein Intervention Trials (HIT), will be presenting data from HIT on Wednesday, November 11 at 1:00 pm during the American Heart Association Conference.


'"/>

Contact: Karen Peart
k.peart@noonanrusso.com
212-696-4455 ext.343
Noonan/Russo Communications
15-Oct-1998


Page: 1

Related biology news :

1. Study Ensures Effective Ways To Measure Macular Pigment Density
2. Reanalysis Of International Data Finds Sharp Decline In Sperm Density
3. Depression A Risk Factor For Coronary Artery Disease In Men
4. American Heart Association Comment: "Folate And Vitamin B6 From Diet And Supplements In Relation To Risk Of Coronary Heart Disease Among Women"
5. Heart gene yields insights into evolution, disease risk
6. Heartless worms hold clues to cardiac arrhythmias, sudden death
7. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
8. Heart and lung transplantation clinical trial results to be announced at ISHLT meeting
9. Heart may heal with help from oxygen-sensitive genes, new study suggests
10. Heart drug might help fight chronic fungal infections
11. Heart disease among some Japanese may be due to sequencing variation inside a gene

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: High Density Lipoproteins And Coronary Heart Disease

(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: